HOME / SCIENCE / RAS pathway and cancer
RAS GTPase family has 3 members encoding KRAS, HRAS and NRAS proteins which are involved in controlling normal growth signal. RAS GTPases are also well-known oncogenes that drive tumorigenesis when mutation is acquired. RAS oncogene mutations have been documented in more than 25% of total cancer patients worldwide and in cancer patients of Lung, Colon and Pancreas with high frequencies, especially. There were many attempts to find the effective drug to treat cancer patients with RAS mutation for last 40 years without success. Consequently, RAS protein was considered as an undruggable target. However, impressive clinical responses were observed in trial of Lumakras (sotorasib, Amgen) and Kraziti (adagrasib, Mirati) utilizing compound’s ability to form covalent bond with cysteine specifically in KRASG12C mutated cancer (14% of KRAS mutated cancers). The successful approval of Lumakras is heightened driving hope and anticipation of developing therapeutics to treat KRAS mutated cancer.
At Txinno Bioscience, we are developing “ULK1” inhibitor (best-in-class), “Target S” inhibitor (best-in-class), “Target I” inhibitor (best-in-class) and “Target Y“ inhibitor (first-in-class) to treat cancer patients with KRAS mutations.
ULK1 is a serine/threonine protein kinase that involved in initiating autophagy process when cells encounter stressful conditions, like starvation or oxidative assaults. Autophagy has been known to play important roles in survival, drug resistance as well as immune avoidance of cancer cells. Interestingly, inhibition of ULK1 has been reported to enhance the efficacy of MEK kinase inhibitor when KRAS-mutated cancer cells were subjected to inhibition of both kinases simultaneously (Bryan D. Smith, et. al. (2019) AACR-EORTC poster presentation).
At Txinno Bioscience, we are developing two small molecule drug candidates based on synthetic lethality relationship, ULK1 inhibitor (ULK1 and MEK protein kinases) and ’Target Y’ inhibitor (target Y and metabolic vulnerability of cancer) with distinct advantages; 1) compared to KRASG12C inhibitors, like Lumakras, treatment of these candidates with appropriate combination partner will be effective to patients with to patients with other KRAS mutations as well as with KRASG12C mutation, 2) there is a possibility of providing similar or higher clinical effectiveness with same or reduced dose of combination partner.
Recently, Lumakras and Krazati which are KRASG12C inhibitors by forming covalent bond with mutated KRAS protein were approved by FDA and are leading a great advancement of treating non small cell lung cancer patients. However, because the approved G12C inhibitors exert their inhibitory activities by forming covalent bond with cysteine residue only found in 14% patients among all KRAS mutated cancer patients, there is a significant limitation of lack of benefit against other KRAS mutations which occurs in rest of 85% KRAS mutation cancer patients. Also, recent publication showed that about 30% of KRASG12C cancer patients treated with G12C inhibitor (Adagrasib, Mirati) eventually developed drug resistance acquired by additional mutation other than G12C. There is a tremendous demands on new drug against KRAS mutated cancer harboring mutations other than G12C.
At Txinno Bioscience, we are developing small molecule ’Target S’ inhibitor and ’Target I’ inhibitor that directly inhibit mutant KRAS protein. These inhibitors has advantages of treating larger population of KRAS mutated cancer patients than that of KRASG12C carrying patients